APOB and Hypercholesterolemia: It can be assumed that the “anti-atherosclerotic” potential of PCSK9-inhibition is similar in FDBL, mixed hyperlipidemia and hypercholesterolemia as the concentration of apoB-containing lipoproteins is reduced to a similar extent.